Allarity Therapeutics (NASDAQ:ALLR) Stock Price Expected to Rise, Ascendiant Capital Markets Analyst Says

Allarity Therapeutics (NASDAQ:ALLR) had its target price boosted by Ascendiant Capital Markets from $9.50 to $9.75 in a research report issued to clients and investors on Friday,Benzinga reports. The brokerage currently has a “buy” rating on the stock.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Allarity Therapeutics in a research note on Wednesday, January 21st. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Allarity Therapeutics currently has an average rating of “Hold” and a consensus target price of $9.75.

Allarity Therapeutics Stock Up 10.4%

Allarity Therapeutics stock opened at $1.27 on Friday. The business has a 50-day simple moving average of $1.05 and a two-hundred day simple moving average of $1.19. The company has a market cap of $20.09 million, a P/E ratio of -1.59 and a beta of 0.01. Allarity Therapeutics has a 52-week low of $0.66 and a 52-week high of $2.35.

Allarity Therapeutics (NASDAQ:ALLR) last released its quarterly earnings results on Monday, March 30th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.01. Research analysts anticipate that Allarity Therapeutics will post -78.08 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in ALLR. Private Advisor Group LLC purchased a new position in Allarity Therapeutics in the 3rd quarter worth approximately $441,000. Renaissance Technologies LLC raised its holdings in shares of Allarity Therapeutics by 274.1% during the 4th quarter. Renaissance Technologies LLC now owns 247,612 shares of the company’s stock worth $267,000 after acquiring an additional 181,426 shares in the last quarter. DRW Securities LLC purchased a new stake in shares of Allarity Therapeutics during the 4th quarter worth approximately $133,000. Capital Advisors Inc. OK purchased a new stake in shares of Allarity Therapeutics during the 4th quarter worth approximately $108,000. Finally, Citadel Advisors LLC purchased a new stake in shares of Allarity Therapeutics during the 3rd quarter worth approximately $149,000. 11.53% of the stock is owned by hedge funds and other institutional investors.

About Allarity Therapeutics

Allarity Therapeutics A/S (NASDAQ:ALLR) is a clinical‐stage biotechnology company focused on advancing precision medicine in oncology and other severe diseases. The company leverages predictive biomarkers and proprietary companion diagnostic tools to identify patient populations most likely to respond to its therapeutic candidates. By integrating molecular profiling early in development, Allarity aims to improve clinical trial success rates and accelerate the path to regulatory approval.

The company’s lead pipeline includes novel small‐molecule inhibitors engineered to target key pathways in solid tumors, with two primary assets currently in mid‐stage clinical trials.